A Review on People Affected by Omicron Even After Complete Vaccination

Nimisha Gaikwad[1], Shreya Dhepe[2], Chetan Masram[3]

[1,2,3,4]*Department of Biotechnology Engineering, MGM College Of Engineering and Technology, Kamothe.*

Abstract - *The world was still sick from the chaos caused by the delta variant; however, by then, the alphabetic character had arrived. Omicron (B.1.1.529) has been declared a variant of concern by the United Nations agency determined that it had multiple mutations supported knowledge. everyone seems to be speculative why the alphabetic character is being affected even when obtaining unsusceptible. The answer to the present is obvious: the Covid-19 vaccines utilized in most of the world provide virtually negligible to no defense against infection by the highly contagious alphabetic character variant, all because it carries an associate abundance of distinctive mutations; on the spike supermolecule that is that the infectious agent supermolecule that there are additional than 30. These mutations are the unique feature of alphabetic character, which gives a facet step to avoid previous vaccines. In Nov, the alphabetic character was 1st known in African nations and South Africa associated caused a fearful spike in COVID-19 cases in the African country. Many studies show that the alphabetic character is much more contagious than the previous variants, which is a concern section. Still, luckily, it's less severe than a delta. Still, it sure is true that susceptible folks are at more considerable risk once compared to people who are unsusceptible, and therefore the same is the case with the older age group; this could not be considered gentle. Alphabetic characters created the planet to understand that the pandemic was far away from being over which, they had to follow the guidelines given. Like the alphabetic character, this variant can stick with it emerging since it's a natural part of the virus's progression. Shortly, there are high possibilities of a brand new variant developing, and the indisputable fact that alphabetic character would be the last variant should not be shocking as long as a COVID-19 epidemic happens somewhere on the world.*

Key Words: Omicron, SARS-COV-2, Covishield, Covaxin, Pfizer.

1.INTRODUCTION

The COVID-19 pandemic (coronavirus) has become an enormous threat to the whole world, making people confined in their homes and restricting their mobility. It has a pervasive influence on people's daily lives and health, including significant mortality among older folks and those with pre-existing health issues. It even has a remarkable impact on the global economy. In this review paper, we will be discussing the newly discovered variant which belongs to the Pango lineage B.1.1.529 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) from South Africa in Botswana named Omicron by the World Health Organization (WHO) on November 24, 2021(He et al., 2021) [1]. This variant caused a tremendous hike in coronavirus cases that WHO categorized the Omicron variants as a Variant of Concern (VOC).

The variant has a high risk of re-infection compared to other variants and has very high transmissibility. Concerning factor is its large number of mutations (i.e., more than 50 and of these, 32 mutations has been seen in spike protein), increase in virulence, the sudden rise in the number of cases of this variant, and disease severity put forward the emerging risk of global public health. PCR test is used for this variant as one of three target genes is not detected (S gene target failure), leading to faster detection rates. The Omicron variant of SARS-CoV-2 displays substantial evidence for elusion of immunity from prior infection. The percentage of conditions similar to the Beta variant increased to ~50% of the daily requirements within roughly 100 days since its outbreak. That Delta variant raised to ~80% during the same amount of time. In comparison, the percentage of Omicron infection reached ~90% in almost 25 days making it more infectious than other variants [2]. The Omicron variant is 91% less likely to cause death in infected patients and makes shorter hospital stays for infected patients. [3]

The variant has a two-thirds reduction in the COVID-19 hospitalization rates and a decrease in risk of severe disease in SGTF(S gene target failure)-infected individuals to that of Delta-infected individuals, eventually resulting in high population immunity. So to increase population immunity, prevent severe disease, and reduce the developing health crisis, vaccines play a significant role. Booster doses are allotted in some countries. To date, ten vaccines have been authorized by WHO.

Individuals are prompted to take adequate measures such as wearing well-fitting masks, keeping physical distance, washing hands, improving the ventilation of indoor spaces, avoiding crowded areas, and getting vaccinated to minimize the risk of COVID-19.

2. Symptoms

According to the WHO, there are no different symptoms of Omicron other than usual covid-19 symptoms. The WHO also aforesaid that the mortality rate of the omicron variant can be specifically high. The omicron variant is more of upper respiratory tract symptoms and more minor of fever; all the

signs of these variants of Covid-19 are primarily on the milder side; therefore, it is difficult to detect it only by symptom algorithms[4]. Some of the symptoms of the omicron variant are as follows:

1. Headache

2. Cough

3. Shortness of breath

4. Fever

5. Fatigue

6. Sore throat

7. Muscle or body aches

8. A loss of taste or smell

9. A runny nose

3. Epidemiology

In November 2021, there was an increase in COVID-19 incidents in South Africa due to Omicron. A notable feature of this variation is that they expressed an overdose. This diversity spread to neighboring provinces of South Africa. And also the closest countries, such as Namibia, Zimbabwe, Botswana, Mozambique, and many more. Many countries have travel restrictions for passengers from South Africa. Egypt, Belgium, Malaysia, India, and Sri Lanka have reported new cases due to increased Omicron diversity. People's immune systems deteriorate day by day as infection levels rise, weakening those who have already been vaccinated [5]. It is maybe due to some changes, particularly in the S-protein of the Omicron variant. This species may be more dangerous than the Delta diversity that has caused fewer deaths in India. The Delta variant showed only eight changes in spike protein, while the Omicron variant showed more than 30 amino acid mutations.[6] The most widely used PCR may not find this exception with numerous Omicron genetic mutations. Omicron variants with high reactivation potential may affect previously infected patients with COVID-19. In addition, many patients infected with the Omicron variant were younger patients who were school students. Not detailed studies on Omicron's differences in pathogenesis, virulence, and mutation profiles are available. More experimentation is required in this field to acknowledge these differences [7].

4. Content of Vaccine

The World Health Organization has clinically accredited and allowed ten vaccines by ensuring their safety and effectiveness for the prevention of SARS-CoV-2, and there by getting people vaccinated to increase their immune system.

4.1 Pfizer/BioNTech

Comirnaty: Pfizer-BioNTech is an anti-COVID-19 mRNA vaccine. Also referred to as Tozinameran, BNT162b2 has already been given emergency authorization from December 2020. The basic constituent of Pfizer's Vaccine is that it contains nucleoside-modified messenger RNA (Moderna) encoding the viral spike glycoprotein (S) of SARS-CoV-2 as its active ingredient. It consists of four different lipids i.e. (2-hexyldecanoate),2-[(polyethylene glycol)-2000]-N,N-di-tetradecyl acetamide (ALC-0159), 1,2-distearoyl-sn glycerol-3-phosphocholine (DPSC), Cholesterol and (4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis (ALC-3015) being its primary ingredient due to its ionizable property. Potassium chloride, monobasic potassium phosphate, sodium chloride, and basic sodium phosphate dehydrate are the four salts in the Vaccine, forming phosphate-buffered saline (PBS) and sucrose content; it is a preservative-free vaccine. Pfizer's vaccine countries exhibit 91% effectiveness in preventing COVID-19.[8]

4.2 Moderna Spikevax

Moderna/ Spikevax is a lipid nanoparticle-encapsulated mRNA vaccine referred to as mRNA-1273. It has 94.1% effectiveness forestalling against COVID-19. The contents of the Moderna vaccine is messenger ribonucleic acid (mRNA), lipids such as (polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG], SM-102 cholesterol, and 1,2-distearoyl-sn-glycerol-3-phosphocholine [DSPC]), a salt such as tromethamine, tromethamine hydrochloride, sucrose, acetic acid, sodium acetate trihydrate and it has no preservative.[9]

4.3 Janssen (Johnson & Johnson)

Ad26.COV2.S Johnson & Johnson Vaccine is a Non-Replicated Viral Vector vaccine, also referred to as Ad26COVS1, JNJ-78436735. The efficiency of the Vaccine is 66.9% based on clinical trials. The vaccine ingredients are replication-incompetent recombinant adenovirus type 26 expressing the SARS-CoV-2 spike protein, citric acid monohydrate, trisodium citrate dihydrate, ethanol, two hydroxypropyl-β-cyclodextrin (HBCD), polysorbate-80, sodium chloride, and no preservatives.[9]

4.4 Serum Institute of India

Covishield (Oxford/ AstraZeneca formulation): Chadox1 Nov-19 Corona Virus Vaccine uses a replication-deficient chimpanzee viral (adenovirus) vector referred to as AZD1222. The effectiveness of Covishield is 70.4% in limiting symptomatic COVID-19 occurrence. Covishield/ Astrazeneca has inactivated adenovirus with segments of Coronavirus, Aluminium Hydroxide Gel, chemical ingredients such as L-Histidine, L-Histidine Hydrochloride Monohydrate,

Magnesium Chloride Hexahydrate, Polysorbate 80, Ethanol, Sucrose, Sodium Chloride, and Disodium Edetate Dihydrate (EDTA).[10]

4.5 Bharat Biotech:(Covaxin)

Covaxin is also referred to as BBV152. The Vaccine is derived from Whole-Virion Inactivated Vero Cell with an efficiency of 77.8% against COVID-19 disease. Covaxin contains ingredients such as whole-virion inactivated SARS-CoV-2 antigen (Strain: NIV-2020-770), Aluminum hydroxide gel, TLR 7/8 agonist, (imidazoquinolinone) 2-phenoxyethanol, and phosphate buffer saline.[11]

The other approved are Novavax: Nuvaxovid, also be referred to as NVX-CoV2373, Serum Institute of India: COVOVAX (Novavax formulation), Sino pharm (Beijing): Covilo, also be referred to as BBIBP-CorV (Vero Cells) and Sino vac: Corona Vac.[12]

5. SARS-COV-2 Omicron Variant

The Omicron variant (B.1.1.529) was first reported to the World Health Organization (WHO) on November 24, 2021, as a mutation of SARS-CoV-2 (the virus that causes COVID-19). Within the bronchi (lung airways), Omicron grows 70 times faster than the Delta variation, but when compared to the Delta variant, however, data suggests it is less severe than prior strains. Omicrons are less ready for deep lung towels. Studies show that Omicron infections are 91 lower dangerous than the delta variant, with 51 lower threats of hospitalization. Still, the estimated difference in natural hospitalization threat vastly decreases to 0-30 percent when reinjections are blinked. Overall, the unusually high spread rate, along with the fact that its capability to evade both double vaccination and thus, the body's system, means the total number of cases taking sanitarium care at any given time remains of great concern.

Vaccines continue to cover against severe complaints and hospitalization, especially after the third cure of an mRNA vaccine is given. Beforehand numbers suggest that double vaccination offers 30 to 40 percent protection against infection and around 70 percent protection against hospitalization.

The symptoms and inflexibility of their recent COVID-19 infection are analogous to or milder than the first infection. There-infected cases just endured minor current signs, no loss of taste or smell, are suffered from then. Compared with symptoms reported during their first infections, patients who are not vaccinated without a former COVID-19 opinion can witness cough, everyday pain, traffic, fever, and chills. No bone needed hospitalization for either their first or alternate infections.[13]

6. Location in Human Body where Omicron affects

SARS-CoV-2 infects the epithelium cells in multiple organs and causes diffuse lymphocytic endothelins, panning come in constriction. For utmost cases, COVID-19 begins and ends in their lungs; coronaviruses square measure metabolic process disorders due to a bit like the flu. Typically, they unfold once an Associate in Nursing infected person coughs or sneezes, scattering droplets that transmit the virus to anyone in shut contact. Coronaviruses conjointly cause flu-like symptoms. Cases may begin with a fever and cough that progresses to respiratory illness or worse. When the severe acute respiratory syndrome occurrence, the planet Health Organization reportable that the disease usually attacked the lungs in 3 phases infective agent replication, immune hyperreactivity, and respiratory organ destruction. The novel coronavirus invades human respiratory organ cells within Associate in Nursing infection in haste. Those respiratory organ cells square measure out there in 2 categories ones that build mucous secretion and ones with hair-like batons referred to as cilia. Severe acute respiratory syndrome darling to infect and kill cilia cells that then sloughed off and stuffed patients 'airways with junk and fluids. He hypothesizes that the same is going on with the novel coronavirus. That is because the earliest studies on COVID-19 have shown that plenty of cases develops pneumonia in each lung amid symptoms like shortness of breath. That is once section 2 and the system kicks in. Aroused by the presence of an infective agent intruder, our bodies intensify to fight the sickness by infusing immune cells into the lungs to remove the damage and repair the respiratory organ towel. Once operating correctly, this inflammatory method is tightly regulated and confined solely to infected areas. however, generally, your system goes haywire, and folk's cells kill something in their means, as well as your healthy towel. "As a result, the immune response causes more injury rather than less," Furthermore, material plugs the lungs, worsening respiratory sickness. Throughout the third section, respiratory organ injury continues to make, resulting in metabolic process failure. Even supposing death does not occur, some patients survive with permanent respiratory organ injury. Consistent with the World Health Organization, SARS punched holes inside the lungs, giving them "a honeycomb-like appearance" — and these lesions square measure gift in those afflicted by a unique coronavirus, too. These holes square measure doubtless created by the immune system's overactive response, which makes scars that each protects and stiffen the lungs. Once that happens, patients typically have to be compelled to be placed on ventilators to assist their respiration. Meanwhile, inflammation conjointly makes the membranes between the air sacs and blood vessels additional leaky; This can cause the lungs to swell with fluid, impairing their ability to handle blood[14]

7. Why is Omicron Affecting even after Complete Vaccination ?

The omicron variant affects the human body even once complete vaccination because Omicron escapes the bulk of existing SARS-CoV-2 neutralizing antibodies.[15] The clan is characterized by all the thirty-two mutations within the spike, set principally within the N-terminal domain (NTD) and, therefore, the receptor-binding domain (RBD), enhancing the variant fitness and permitting antibody evasion. An examination of its sensitivity to 9 monoclonal antibodies to antibodies present in 115 sera from COVID-19 vaccine recipients or convalescent individuals antibodies present in 115 sera from COVID-19 vaccine recipients or convalescent individuals. All mAbs examined failed to neutralize Omicron entirely or partially; however, a booster Pfizer dose, as well as vaccination of already infected patients, elicited an anti-Omicron neutralizing response, with titers 6-23 times lower against Omicron than against Delta [16]. As a result, most therapeutic monoclonal antibodies and, to a considerable extent, vaccine-elicited antibodies fail to recognize Omicron. On the other hand, Omicron is still neutralized by antibodies produced by a booster vaccine dosage. An investigation was set up to check whether sera's compelling and binding activity from convalescent, mRNA double vaccinated, mRNA boosted, convalescent double vaccinated, and convalescent boosted individuals against wild type, B.1.351 and B.1.1.529 SARS-CoV-2 isolates or not. As a result, neutralizing activity of sera from convalescent and double unsusceptible participants was undetectable to terribly low against B.1.1.529 whereas neutralizing activity of sera from people World Health Organization had been exposed to spike 3 or 4 times was maintained, albeit at considerably reduced levels. Binding to the B.1.1.529 receptor-binding domain (RBD) and N-terminal domain (NTD) was decreased in convalescent, not unsusceptible people; however, Vaccine principally maintained it in immune people.[17]

8. Current Research

Researchers of the University of Liverpool used a mouse model to assess and finds that those mice infected with omicron variant experience less severity in their clinical ramification of infection (i. e. less weight, have lower viral loads in both lower and upper respiratory tract, and less extensive inflammation in lungs) than other variants. They also proposed that the Omicron variant is most likely to infect the throat explaining its high transmissibility and low deadliness.[18]

Research made in vivo study on infectivity of the Omicron variant on Syrian hamsters concludes that it is unable to replicate in the lower respiratory tract, has no signs of bronchopneumonia, and has a low viral load in comparison with D614G strain and other VOCs.[19]

Researchers of the University of Hong Kong used ex vivo respiratory tract cultures to understand why the Omicron variant may differ in transmissibility and disease severity. They constitute that compared to the novel SARS-CoV-2 virus and the Delta variant, the Omicron variant replicates 70 times faster in human bronchus after 24 hours of infection. In human lung tissue, it replicates ten times lower than original SARS-CoV-2 resulting in lower severity of the disease.[20]

9. CONCLUSIONS

The third/booster vaccine dose provides significant extra protection against the risk of symptomatic disease. COVID-19 is a code for Omicron. When the immune system responds to an illness, it is not always obvious how long any developed immunity will last. Even if people become infected due to vaccination or natural infection, they will likely have a moderate illness. Immune responses in older adults, for example, may be weakened. A quick, global immunization campaign in conjunction with other public health measures to stop transmission is the most robust defense against the introduction of new variations of concern."

REFERENCES

[1] He, W. Hong, X. Pan, G. Lu, and X. Wei, "SARS-CoV-2 Omicron variant: Characteristics and prevention", MedComm, vol. 2, no. 4, pp. 838-845, 2021. Available: 10.1002/mco2.110.

[2] "Omicron is very lenient to Cause Death Than Delta Variant," Health line, 2022. [Online]. Available: https://www.healthline.com/health-news/omicron-is-91-percent-less-likely-to-cause-death-than-delta-variant. [Accessed: 30- Jan- 2022].

[3] M. Mohiuddin and K. Kasahara, "Investigating the aggressiveness of the COVID-19 Omicron variant and suggestions for possible treatment options", Respiratory Medicine, vol. 191, p. 106716, 2022. Available: 10.1016/j.rmed.2021.106716 [Accessed 30 January 2022].

[4] G. Iacobucci, "Covid-19: Runny nose, headache, and fatigue are commonest symptoms of omicron, early data show", BMJ, p. n3103, 2021. Available: 10.1136/BMJ.n3103.

[5] G. Lippi, C. Mattiuzzi and B. Henry, "Is SARS-CoV-2 Omicron (B.1.1.529) variant causing different symptoms?", 2022. Available: 10.21203/rs.3.rs-1214484/v1 [Accessed 30 January 2022].

[6] M. Rae, "Official list of covid-19 symptoms must be updated", BMJ, p. o121, 2022. Available: 10.1136/BMJ.o121 [Accessed 30 January 2022].

[7] E. PMC, "Europe PMC", Europepmc.org, 2022. [Online]. Available: https://europepmc.org/article/med/34982466. [Accessed: 30- Jan- 2022].

[8] "What are the elements of Pfizer's covid-19 vaccine?" MIT Technology, 2022. [Online]. Available: https://www.technologyreview.com/2020/12/09/1013538/what-are-the-ingredients-of-pfizers-covid-19-vaccine/. [Accessed: 30- Jan- 2022].

[9] "What is the overall List of the COVID-19 Vaccine Ingredients?", CT.gov - Connecticut's Official State Website, 2022. [Online]. Available: https://portal.ct.gov/Coronavirus/Covid-19-Knowledge-Base/Vaccine-Ingredients. [Accessed: 30- Jan- 2022].

[10] S. vaccine, "Serum Institute of India obtains emergency use authorization in India for AstraZeneca's COVID-19 vaccine", Astrazeneca.com, 2022. [Online]. Available: https://www.astrazeneca.com/media-centre/press-releases/2021/serum-institute-of-india-obtains-emergency-use-authorisation-in-india-for-astrazenecas-covid-19-vaccine.html.

[11] "COVAXIN - India's First Indigenous Covid-19 Vaccine | Bharat Biotech", Bharatbiotech.com, 2022. [Online]. Available: https://www.bharatbiotech.com/covaxin.html.

[12] "WHO–COVID19Vaccine Tracker", Covid19.trackvaccines.org, 2022. [Online]. Available: https://covid19.trackvaccines.org/agency/w.

[13] "MMWR COVID-19 reports," Centers for Disease Control and Prevention, 27-Jan-2022. [Online]. Available: https://www.cdc.gov/mmwr/Novel_Coronavirus_Reports.html.

[14] McKeever, Amy. "Here is What Coronavirus Does to the Body." Science, National Geographic, May 3, 2021, https://www.nationalgeographic.com/science/article/here-is-what-coronavirus-does-to-the-body.

[15] Planas, D., Saunders, N., Maes, P. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature (2021). https://doi.org/10.1038/s41586-021-04389-z

[16] Cao, Y., Wang, J., Jian, F. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature (2021). https://doi.org/10.1038/s41586-021-04385-3

[17] Carreño, J.M., Alshammary, H., Tcheou, J., et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.Nature(2021). https://doi.org/10.1038/s41586-022-04399-5

[18] "Omicron leads to less severe disease in mice; study finds - Articles - Research - the University of Liverpool," Liverpool. Ac.UK, 2022. [Online]. Available: https://www.liverpool.ac.uk/research/news/articles/omicron-leads-to-less-severe-disease-in-mice-study-finds/.

[19] R. Abdelnabi et al., "The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters", Antiviral Research, vol. 198, p. 105253, 2022. Available:https://www.sciencedirect.com/science/article/pii/S0166354222000213.

[20] 2022.[Online].Available: https://www.med.hku.hk/en/news/press/20211215-omicron-sars-cov-2-infection.